La cadena de opciones muestra datos clave de las opciones de acciones de USA Rare Earth a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para USA Rare Earth..

USA Rare Earth (NASDAQ:USARW) Bolsa, Cadena de Opciones

USA Rare Earth Inc is a vertically integrated, domestic rare earth magnet supply chain that supports the state of energy, mobility, and national security in the United States. USARE is developing an NdFeB magnet manufacturing plant in the United States, and establishing domestic rare earth and critical minerals supply, extraction, and processing capabilities to both supply its manufacturing plant and market surplus materials to third parties. Rare earth magnets are critical to various business sectors and industries, including the defense, automotive, aviation, industrial, medical and consumer electronics industries.

USA Rare Earth Inc

California Water Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.58 by 22.84 percent. This is a 1.43 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $264.95 million which beat the analyst consensus estimate of $243.46 million by 8.83 percent. This is a 8.45 percent increase over sales of $244.30 million the same period last year.

Earnings

Earnings Beats

News

California Water Servs Gr Q2 Adj. EPS $0.71 Beats $0.58 Estimate, Sales $264.95M Beat $243.46M Estimate

WIIM

LUNG

Pulmonx shares are trading lower after the company reported Q2 financial results and cut its FY25 sales guidance below estimates. Also, Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $9 to $2.5, while D. Boral Capital cut its price target from $17 to $16.

BINI

Bollinger Innovations shares are trading lower after announcing a 1-for-250 reverse stock split effective August 4.

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.18 by 18.03 percent. This is a 21.05 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $53.383 million which beat the analyst consensus estimate of $53.218 million by 0.31 percent. This is a 23.01 percent decrease over sales of $69.339 million the same period last year.

Earnings Misses

UPLD

Upland Software Q2 Adj. EPS $0.15 Misses $0.18 Estimate, Sales $53.383M Beat $53.218M Estimate

Cantor Fitzgerald analyst Deepak Mathivanan maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and raises the price target from $69 to $85.

Price Target

Analyst Ratings

EBAY

Cantor Fitzgerald Maintains Neutral on eBay, Raises Price Target to $85

FGIWW

Trading Halt: Halt status updated at 9:01:45 AM ET: Quotation Resumption: News and Resumption Times

Spring Valley Acquisition Corp. II - Rights

SVIIR

SVIIU

SVIIW

Stock Split

Bollinger Innovations Announces 1-for-250 Reverse Split, Effective Aug. 4

PSTV

Plus Therapeutics shares are trading higher after the company announced the launch of CNSide Diagnostic in Texas.

Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) narrows FY2025 Adj EPS guidance from $0.75-$1.00 to $0.75-$0.95 vs $0.84 analyst estimate..

Guidance

SNDR

Schneider National Narrows FY2025 Adj EPS Guidance from $0.75-$1.00 to $0.75-$0.95 vs $0.84 Est

Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $2.30 by 3.78 percent. This is a 8.14 percent increase over earnings of $2.21 per share from the same period last year. The company reported quarterly sales of $546.877 million which missed the analyst consensus estimate of $552.535 million by 1.02 percent. This is a 7.67 percent increase over sales of $507.902 million the same period last year.

Cullen/Frost Bankers Q2 EPS $2.39 Beats $2.30 Estimate, Sales $546.877M Miss $552.535M Estimate

4 analysts have shared their evaluations of CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.5, a high estimate of $7.00, and a low estimate of $5.00. Marking an increase of 31.89%, the current average surpasses the previous average price target of $4.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1753966869_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of CytomX Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CytomX Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CytomX Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CytomX Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CytomX Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTMX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CytomX Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering CytomX Therapeutics: A Closer Look</h2>
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
<h3>A Deep Dive into CytomX Therapeutics's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, CytomX Therapeutics showcased positive performance, achieving a revenue growth rate of 22.8% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CytomX Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 46.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 191.31%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CytomX Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 21.48%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.33, CytomX Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)

UBS analyst Joshua Spector maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Buy and raises the price target from $29 to $30.

UBS Maintains Buy on Element Solutions, Raises Price Target to $30

GSK's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) short percent of float has fallen 27.17% since its last report. The company recently reported that it has 13.51 million shares sold short, which is 0.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>GSK Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753966862_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GSK has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GSK's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, GSK's peer group average for short interest as a percentage of float is 3.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About GSK?

Throughout the last three months, 7 analysts have evaluated Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $92.29, a high estimate of $102.00, and a low estimate of $88.00. This upward trend is evident, with the current average reflecting a 7.53% increase from the previous average price target of $85.83.
<img src="https://www.benzinga.com/files/images/story/2025/1753966860_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Axos Financial among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Daniel Tamayo</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axos Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axos Financial compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axos Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Axos Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axos Financial analyst ratings.</a>
<h2>Get to Know Axos Financial Better</h2>
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
<h3>Key Indicators: Axos Financial's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Axos Financial showcased positive performance, achieving a revenue growth rate of 4.94% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 34.53%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Axos Financial's ROE stands out, surpassing industry averages. With an impressive ROE of 4.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Axos Financial's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.44%, the company showcases efficient use of assets and strong financial health.
Debt Management: Axos Financial's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Axos Financial Stands With Analysts

Marsh &amp; McLennan Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has fallen 16.43% since its last report. The company recently reported that it has 5.72 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753966856_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan Cos has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Marsh &amp; McLennan Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Marsh &amp; McLennan Cos's peer group average for short interest as a percentage of float is 3.88%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Marsh & McLennan Cos?

Corning's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) short percent of float has fallen 3.98% since its last report. The company recently reported that it has 12.71 million shares sold short, which is 1.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Corning Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753966851_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Corning has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Corning's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Corning's peer group average for short interest as a percentage of float is 3.59%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Corning's Recent Short Interest

Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 3.45 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.421 billion which beat the analyst consensus estimate of $1.415 billion by 0.42 percent. This is a 7.86 percent increase over sales of $1.317 billion the same period last year.

Schneider National Q2 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $1.421B Beat $1.415B Estimate

Press Releases

USA Rare Earth Announces Date for First Quarter 2025 Results and Conference Call

USA Rare Earth and The StudBuddy® Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets

Financing

USA Rare Earth Announces $75 Million PIPE Investment

USA Rare Earth Announces Closing of $75 Million PIPE Financing

USA Rare Earth Reports its First Quarter 2025 Financial Results

Contracts

USA Rare Earth and PolarStar Innovations Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets

Management

USA Rare Earth Announces Appointment of David Bushi as Senior Vice President of Manufacturing

USA Rare Earth and Moog Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets for Data Center Cooling Solutions

USA Rare Earth Bolsters Global Sales Effort with Appointment of Ron Fogarty as Vice President of Sales

USA Rare Earth Announces Date for Second Quarter 2025 Results and Conference Call

USAR

USARW

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

Comments

USA Rare Earth

USA Rare Earth (USARW) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL